Alerts
Want to monitor KROS?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor KROSWant to monitor KROS?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor KROSKeros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis.